NFKB1 and neoplasm: Therefore, our current investigation also provides insights to establish a foundation to devise new synthetic lethal strategies by combining CHK1 or PARP1 inhibitors with TOP1 inhibitors to counteract WRN and NF‐κB mediated intrinsic tumor resistance in clinical settings.